부산대학교 도서관

Colchicine is a broad‐acting anti‐inflammatory agent that has attracted interest for repurposing in atherosclerotic cardiovascular disease. Here, we studied its ability at a human equivalent dose of 0.5 mg/day to modify plaque formation and composition in murine atherosclerosis and investigated its actions on macrophage responses to atherogenic stimuli in vitro. In atherosclerosis induced by high‐cholesterol diet, Apoe−/− mice treated with colchicine had 50% reduction in aortic oil Red O+ plaque area compared to saline control (p =.001) and lower oil Red O+ staining of aortic sinus lesions (p =.03). In vitro, addition of 10 nM colchicine inhibited foam cell formation from murine and human macrophages after treatment with oxidized LDL (ox‐LDL). Mechanistically, colchicine downregulated glycosylation and surface expression of the ox‐LDL uptake receptor, CD36, and reduced CD36+ staining in aortic sinus plaques. It also decreased macrophage uptake of cholesterol crystals, resulting in lower intracellular lysosomal activity, inhibition of the NLRP3 inflammasome, and reduced secretion of IL‐1β and IL‐18. Colchicine's anti‐atherosclerotic actions were accentuated in a mouse model of unstable plaque induced by carotid artery tandem stenosis surgery, where it decreased lesion size by 48% (p =.01), reduced lipid (p =.006) and necrotic core area (p =.007), increased collagen content and cap‐to‐necrotic core ratio (p =.05), and attenuated plaque neutrophil extracellular traps (p <.001). At low dose, colchicine's effects were not accompanied by the evidence of microtubule depolymerization. Together, these results show that colchicine exerts anti‐atherosclerotic and plaque‐stabilizing effects at low dose by inhibiting foam cell formation and cholesterol crystal‐induced inflammation. This provides a new framework to support its repurposing for atherosclerotic cardiovascular disease. [ABSTRACT FROM AUTHOR]